Communiqués Azitra, Inc.

Actions

AZTR

US05479L3024

Recherche biotechnologique et médicale

Marché Fermé - NYSE Autres places de cotation 22:00:00 24/07/2026			Varia. 5j.	Varia. 1 janv.
0,1263 ^USD	-0,55 %		-9,14 %	-52,30 %

15/07	Azitra annonce des résultats ex vivo révolutionnaires pour son programme ATR-COSF : doses répétées et efficacité anti-rides	CI
17/06	Les plus fortes hausses en avant-Bourse	MT

Communiqués

15/07	/C O R R E C T I O N -- Azitra, Inc./	PR
17/06	Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond	PR
04/06	Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting	PR
27/05	Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting	PR
13/05	Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates	PR
28/04	Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris	PR
19/03	Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million	PR
13/03	Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement	PR
05/03	Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders	PR
02/03	Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates	AQ
27/02	Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates	PR
24/02	Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash	PR
20/02	Azitra, Inc. to Present at BIO Investment and Growth Summit	AQ
19/02	Azitra, Inc. to Present at BIO Investment & Growth Summit	PR
06/02	Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting	PR
07/01	Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference	PR
17/12	Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American	PR
24/11	Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules	PR
12/11	Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates	PR
07/11	Azitra, Inc. Addresses False Report Regarding Sale of Securities	PR
20/10/25	Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris	PR
06/10/25	Azitra Receives Notice of Non-Compliance from NYSE American	AQ
03/10/25	Azitra Receives Notice of Non-Compliance from NYSE American	PR
04/09/25	Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference	PR
27/08/25	Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash	PR